Boston Scientific
Corporation BSX reported positive three-year follow-up data for the
EVOLVE clinical trial, comparing the safety and performance of the SYNERGY™
Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium (PtCr) Coronary
Stent System to the PROMUS Element™ Stent System.
The data were presented today at EuroPCR 2014 by Professor Ian Meredith,
director of MonashHeart, at Monash Medical Centre in Melbourne, Australia.
The primary clinical and angiographic endpoints of this non-inferiority study
have already been published.
"The SYNERGY Stent three-year results from the EVOLVE trial continue to show
promise with respect to safety and efficacy," said Meredith. "Target lesion
revascularization remains very low, at a rate of 1.1 percent, while there is
no stent thrombosis in the SYNERGY full-dose arm at three years. The EVOLVE
clinical data support the hypothesis that this novel bioabsorbable polymer
stent technology could allow for improved healing over durable polymer DES."
Boston Scientific has expanded its commercial launch of the SYNERGY Stent
System in Europe and in select markets in Asia. It features an ultrathin
abluminal bioabsorbable drug/polymer coating technology which eliminates
long-term polymer exposure. In addition to reducing restenosis, the SYNERGY
Stent System may also offer faster and more complete vessel healing after
stent implantation, potentially reducing the duration of post-procedure dual
antiplatelet therapy.
"The SYNERGY Stent System underscores our ongoing commitment to delivering
meaningful innovation to the interventional cardiology community and is
expected to reinforce our position as a global leader in medical devices,"
said Kevin Ballinger, president, Interventional Cardiology, Boston
Scientific. "The SYNERGY Stent System is uniquely designed to provide
exceptional outcomes in complex cases by promoting early healing and
eliminating long-term polymer exposure.
The SYNERGY Stent System is supported by a rigorous clinical program. Beyond
the EVOLVE Study three-year results, the EVOLVE II Clinical Trial, which
completed enrollment in August 2013, is the pivotal trial designed to support
U.S. Food and Drug Administration and Japanese Ministry of Health, Labor and
Welfare approval of the SYNERGY Stent System. EVOLVE II is a global,
multicenter, randomized, controlled pivotal trial that enrolled 1,684 patients
in 125 sites worldwide, including the U.S., Canada, Europe, Australia, New
Zealand, Japan and Singapore. Additional studies to assess outcomes,
including the potential for reduced dual antiplatelet therapy, will be
supported by Boston Scientific. The SYNERGY Stent System is being
investigated in multiple independent, real-world studies across the spectrum
of cardiovascular disease complexity. For more information on the SYNERGY
Stent System Clinical Program, click here .
The SYNERGY Stent System is an investigational device in the U.S. and Japan,
and is not available for sale in those countries.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in